

BIO-RAD LABORATORIES, INC.  
Form 8-K  
March 18, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report: March 18, 2019**

**(Date of earliest event reported)**

**BIO-RAD LABORATORIES, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation or organization)**

**1-7928**  
**Commission**  
**File Number:**

**94-1381833**  
**(I.R.S. Employer**  
**Identification No.)**

**1000 Alfred Nobel Dr.**

**Hercules, California 94547**

**(Address of principal executive offices, including zip code)**

**(510) 724-7000**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**ITEM 8.01 Other Events.**

On March 4, 2019, Bio-Rad Laboratories, Inc. (the Company) filed a Form 12b-25, or NT 10-K, with the U.S. Securities and Exchange Commission (SEC) to extend the filing deadline for its Annual Report on Form 10-K for the year ended December 31, 2018 (2018 Form 10-K) by the 15 calendar days allotted under Rule 12b-25. At that time, the Company indicated that it expected to file its 2018 Form 10-K on or before the extended deadline of March 18, 2019.

As of March 18, 2019, the Company requires additional time to complete its year end procedures, including its assessment of the effectiveness of the Company's internal control over financial reporting as of December 31, 2018. Therefore, the Company is unable to file its 2018 Form 10-K by the extended filing deadline of March 18, 2019 provided by Rule 12b-25 but intends to complete the filing as promptly as possible thereafter.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIO-RAD LABORATORIES, INC.

Date: March 18, 2019

By: /s/ Timothy S. Ernst  
Timothy S. Ernst  
Executive Vice President, General Counsel and  
Secretary